A major shift in stroke care is underway as tenecteplase outperforms alteplase. This new treatment could redefine recovery ...

All potential acute ischemic stroke patients meeting criteria for the use of IV tPA should be offered treatment. The facts are clear, and all that remains is further provider and patient education.

Intravenous delivered tPA is approved by the FDA for the treatment of acute ischemic stroke. The drug can make a big difference, but only if it is given within a specified time frame (up to four and a ...

Intravenous thrombolysis with recombinant tissue plasminogen activator (rt-PA) is the established treatment for acute ischemic stroke patients presenting within 4.5 h of stroke onset based on the ...

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today announced the peer-reviewed ...

During an ischemic stroke, blood vessels in the brain ... for stroke is to potentially offer a medication called tissue plasminogen activator (TPA) that helps dissolve blood clots.

A study has found that patients with ischemic stroke and COVID-19, compared with patients without COVID-19, experience worse recovery outcomes.

In any case, there was no mortality signal associated with alteplase administered up to 24 hours after a stroke in HOPE. Alteplase and usual care groups had the same 10.8% incidence of 90-day ...

Market Trend: A notable trend in the acute ischemic stroke therapeutics market is the advancement of reperfusion therapies. The use of tissue plasminogen activator (tPA) has been a standard ...

A University of Alabama at Birmingham Heersink School of Medicine-led study suggests that first-time transient ischemic attacks (TIA) are associated with long-term cognitive decline.

Medically reviewed by Brian M. Snelling, MD Certain types of strokes can damage the corona radiata. This bundle of nerve fibers in the brain carries information between cells in the outermost layer of ...

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic ... with tissue plasminogen activator (tPA ...